-+ 0.00%
-+ 0.00%
-+ 0.00%
ImmuCell Says Strong Cash Position Prompts End to At-the-Market Offering
Share
Listen to the news
ImmuCell Says Strong Cash Position Prompts End to At-the-Market Offering
  • ImmuCell reported third-quarter 2026 net income of $953,000, compared with a $140,000 loss a year earlier.
  • Revenue rose 46% to $8.04 million, partly reflecting the absence of distributor restocking headwinds that hurt sales a year earlier.
  • Gross margin increased to 44.2% from 42.9%, reflecting higher pricing and manufacturing execution.
  • Management terminated the At-The-Market offering, citing a strong cash position.
  • A newly negotiated $3 million bank line of credit is expected to be signed in the fourth quarter.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. ImmuCell Corporation published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001437749-26-037731), on November 19, 2026, and is solely responsible for the information contained therein.

Disclaimer:This article represents the opinion of the author only. It does not represent the opinion of Webull, nor should it be viewed as an indication that Webull either agrees with or confirms the truthfulness or accuracy of the information. It should not be considered as investment advice from Webull or anyone else, nor should it be used as the basis of any investment decision.
What's Trending